Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

Part of paid clinical trials in Newport Beach, California.

Sponsor
Aadi Bioscience, Inc.
Study ID
NCT05997056
Phase
PHASE2
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • nab-sirolimus — DRUG
    Prospective phase 2 single arm, open-label, multi-institutional study to determine the efficacy and safety prospective of nab-sirolimus administered by IV infusion

Study Details

A Phase 2 multi-center, open-label, single arm study of nab-sirolimus in patients with well-differentiated neuroendocrine tumors (NETs) of the gastrointestinal tract, lung, or pancreas who have not received prior treatment with mTOR inhibitors

Key Dates

Start date
Nov 7, 2023
Status verified
Jul 2024
Primary completion
May 9, 2025
Completion
Dec 8, 2025

Study Design

Enrollment
21 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: neuroendocrine tumors
    Patients with well-differentiated neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas.

Primary Outcome Measure

Efficacy of nab-sirolimus [ Time Frame: 12 Months ]

Central Contacts

Locations (4)

FacilityCityStateZIPSite coordinators
Hoag Memorial Hospital PresbyterianNewport BeachCalifornia92663
Jason Ledesma
Michael Demeure, MD (PRINCIPAL_INVESTIGATOR)
Rocky Mountain Cancer CentersDenverColorado80218
Jennifer Hedge
Allen Cohn, MD (PRINCIPAL_INVESTIGATOR)
Texas OncologyDallasTexas75246
Christine Terraciano
Scott Paulson, MD (PRINCIPAL_INVESTIGATOR)
Medical College of Wisconsin Cancer CenterMilwaukeeWisconsin53226
Barbara A Dion, CCRC
414-805-4639
Alexandria T Phan, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Newport Beach, CA

By specialty

Related Studies